胃不全麻痺治療市場：薬剤別、疾患タイプ別、投与経路別、エンドユーザー別、地域別、2026～2032年

胃不全麻痺治療市場の評価-2026～2032年

糖尿病性胃不全麻痺治療の世界市場を牽引しているのは、他の疾患との関連リスクの増加、糖尿病性胃不全麻痺の家族歴、遺伝性疾患などです。市場の成長は、標的治療への注目の高まりと政府の好意的な施策によってさらに刺激されると考えられます。このことは、予測期間中の市場成長に多くの機会をもたらすと考えられます。また、急速な都市化、ライフスタイルの変化、頻繁にアルコールやタバコを使用する有病率の増加。さらに、メーカーによる新薬の上市が市場規模を押し上げ、2024年には62億1,342万米ドルを突破し、2032年には約79億521万米ドルの評価額に達する見込みです。

胃不全麻痺に対する現在の薬剤療法に新たなアプローチを導入することを目的とした研究開発研究への継続的な資金提供は、市場成長を増大させると予想されます。外科手術の増加と高齢化は、胃不全麻痺治療市場を2026～2032年までCAGR 3.5%で成長させる主要促進要因です。

胃不全麻痺治療市場定義/概要

胃不全麻痺は、筋運動障害や神経機能障害によって胃の排出が遅れ、その結果、食物が胃に異常に長く留まる病態です。

胃不全麻痺治療市場には、糖尿病、神経疾患、特発性疾患などの要因により引き起こされる胃排出遅延の症状を管理・緩和するための医薬品、医療機器、治療法が含まれ、胃の運動性を改善し、悪心・嘔吐を軽減し、患者のQOLを高めることを目的としています。

胃電気刺激装置は、胃の運動を調節し、胃不全麻痺の症状を緩和するために腹部に植え込まれます。これらの電気刺激装置は胃に電気インパルスを送り、胃排出を改善します。胃不全麻痺の治療法としては、少食で食事回数を増やしたり、液体栄養補助食品を摂取したりするなどの食事療法があります。行動療法やカウンセリングも、症状を管理し、患者の全体的な幸福感を向上させるのに有効です。

胃不全麻痺の治療では、患者個々の要因や重症度を考慮した個別化治療が重視されています。スマートフォンアプリケーションやウェアラブルデバイスのようなデジタルヘルス技術は、症状の遠隔モニタリングに役立ちます。学界、産業、ヘルスケア機関の共同研究がイノベーションを促進し、患者の転帰を改善すると期待されています。

研究開発投資の増加は胃不全麻痺治療市場をどのように牽引するか？

研究開発投資の増加により、製薬会社は胃不全麻痺の新薬、製剤、治療アプローチを革新・開発することができます。研究開発投資の増加により、製薬会社は胃下垂の新薬、製剤、治療アプローチを革新・開発することができます。革新的な治療法を導入し、新薬のパイプラインを充実させることで、これらのメーカーは競合他社との差別化を図り、胃不全麻痺治療市場でより大きなシェアを獲得することができます。

糖尿病罹患率の増加は、糖尿病性胃不全麻痺を発症するリスクのある患者層が拡大していることを意味します。この患者層の拡大は、胃不全麻痺治療を提供する製薬企業、医療機器メーカー、ヘルスケアプロバイダに大きな市場機会をもたらします。

また、糖尿病性胃不全麻痺患者の増加は、新規薬剤、低侵襲性医療機器、胃不全麻痺患者特有のニーズに合わせた先進的治療法の開発など、治療法の革新に拍車をかけています。これらの技術的進歩は、胃不全麻痺治療市場の拡大と多様化に寄与しています。

アルコールとタバコの常用率の上昇と高齢化は、胃不全麻痺の発生率を増加させ、効果的な治療法の需要を促進し、疾病管理における課題を提示し、予防と教育に焦点を当て、オーダーメイドの治療アプローチを必要とすることで、胃不全麻痺治療市場に影響を与える可能性があります。

胃不全麻痺治療のコストと副作用は市場を抑制するか？

胃電気刺激装置や低侵襲外科手術など、胃不全麻痺の先進的治療法には多額の費用がかかることが多いです。これらの費用は、十分な保険が適用されない患者や経済的な余裕のない患者にとって、これらの治療へのアクセスを困難にしています。その結果、患者集団のかなりの部分がこれらの先進治療を受けることができず、その導入が制限され、市場の成長が阻害される可能性があります。

胃不全麻痺治療に関連した重篤な副作用の発生率が高まることで、患者の安全性に対する懸念が高まる可能性があります。規制機関は承認薬の安全性プロファイルを注意深くモニタリングしています。新たな安全性データに基づいて規制や警告が課されることもあります。安全性の問題に対する社会的な認識は、特定の医薬品に対する信頼を損ない、患者や医師によるこれらの治療法の受容を低下させることで市場の成長に水を差す可能性があります。

胃不全麻痺の新薬の承認プロセスは長く複雑です。製薬会社は製品の安全性と有効性を証明するために大規模な前臨床検査と臨床検査を実施しなければならず、これには数年を要し、多額の財政投資が必要となります。薬事承認プロセスの遅延や後退は、新しい治療法のタイムリーな市場導入を妨げ、市場の成長を鈍化させる可能性があります。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション
• 調査手法

第2章 エグゼクティブサマリー

• 主要調査結果
• 市場概要
• 市場ハイライト

第3章 市場概要

• 市場規模と成長の可能性
• 市場動向
• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析

第4章 胃不全麻痺治療市場：薬剤別

• 運動促進薬
• 制吐剤
• ボツリヌス毒素注射
• 栄養サポート

第5章 胃不全麻痺治療市場：疾患タイプ別

• 糖尿病性胃不全麻痺
• 特発性胃不全麻痺
• 術後胃不全麻痺

第6章 胃不全麻痺治療市場：投与経路別

• 静脈内投与
• 経鼻
• 経口

第7章 胃不全麻痺治療市場：エンドユーザー別

• 病院薬局
• 小売薬局
• オンライン薬局

第8章 地域分析

• 北米
• 米国
• カナダ
• メキシコ
• 欧州
• 英国
• ドイツ
• フランス
• イタリア
• アジア太平洋
• 中国
• 日本
• インド
• オーストラリア
• ラテンアメリカ
• ブラジル
• アルゼンチン
• チリ
• 中東・アフリカ
• 南アフリカ
• サウジアラビア
• アラブ首長国連邦

第9章 市場力学

• 市場促進要因
• 市場抑制要因
• 市場機会
• COVID-19の市場への影響

第10章 競合情勢

• 主要企業
• 市場シェア分析

第11章 企業プロファイル

• Evoke Pharma
• AstraZeneca
• Cadila Pharmaceuticals
• Neurogastrx, Inc.
• AbbVie Inc.（Allergan Plc）
• Marel
• Formax
• Weber
• Devro
• Tipper Tie
• Handtmann
• Middleby Corporation
• GEA Group
• Evoke Pharma
• R. Bard, Inc.
• Rhythm Pharmaceuticals, Inc.
• Boston Scientific Corporation
• Kimberly-Clark Corporation
• Vanda Pharmaceuticals

第12章 市場展望市場展望と機会

• 新興技術
• 今後の市場動向
• 投資機会

第13章 付録

• 略語リスト
• 供給源と参考文献

Gastroparesis Treatment Market Valuation - 2026-2032

Increasing risk associated with other diseases, family history of diabetic gastroparesis, and genetic diseases are several factors propelling the global market for diabetic gastroparesis treatment. The market growth will be further stimulated by the increasing focus on targeted therapies and favorable government policies. This will lead to numerous opportunities for the growth of the market during the forecast period. Also, rapid urbanization, changing lifestyles, and an increase in the prevalence of frequent alcohol and tobacco use. Additionally, the launch of novel medications by the manufacturers is driving the market size to surpass USD 6213.42 Million in 2024 to reach a valuation of around USD 7905.21 Million by 2032.

Constant funding for R&D studies aimed at introducing new approaches to the current drug therapy for gastroparesis is anticipated to augment market growth. Increasing surgical procedures and the aging population are the main drivers propelling the gastroparesis medicine market to grow at a CAGR of 3.5% from 2026 to 2032.

Gastroparesis Treatment Market: Definition/ Overview

Gastroparesis is a medical condition causing delayed stomach emptying due to impaired muscle motility or nerve dysfunction, resulting in food remaining in the stomach for an abnormally long period.

The Gastroparesis Treatment Market includes pharmaceuticals, medical devices, and therapies for managing and alleviating symptoms of delayed gastric emptying, caused by factors like diabetes, neurological disorders, or idiopathic reasons, aiming to improve gastric motility, reducing nausea and vomiting, and enhancing patient quality of life.

Gastric electrical stimulation devices are implanted in the abdomen to modulate gastric motility and alleviate symptoms of gastroparesis. These devices deliver electrical impulses to the stomach to improve gastric emptying. Therapeutic approaches for gastroparesis may include dietary modifications, such as eating smaller, more frequent meals or consuming liquid nutritional supplements. Behavioral therapies and counseling may also be beneficial in managing symptoms and improving patients' overall well-being.

The focus is on personalized gastroparesis treatment, considering individual patient factors and disease severity. Digital health technologies, like smartphone applications and wearable devices, can help monitor symptoms remotely. Collaborative research between academia, industry, and healthcare organizations is expected to drive innovation and improve patient outcomes.

How will the Rise in R&D Investments Drive the Market of Gastroparesis Treatment?

Rising R&D investments enable pharmaceutical companies to innovate and develop new drugs, formulations, and treatment approaches for gastroparesis. Rising R&D investments enable pharmaceutical companies to innovate and develop new drugs, formulations, and treatment approaches for gastroparesis. By introducing innovative therapies and maintaining a robust pipeline of novel drugs, these manufacturers can differentiate themselves from competitors and capture a larger share of the Gastroparesis Treatment Market.

The rising incidence of diabetes means a larger pool of patients at risk of developing diabetic gastroparesis. This expanding patient pool presents a substantial market opportunity for pharmaceutical companies, medical device manufacturers, and healthcare providers offering gastroparesis treatments.

Also, the growth in diabetic gastroparesis cases spurs innovation in treatment modalities, including developing novel drugs, minimally invasive medical devices, and advanced therapeutic approaches tailored to the specific needs of gastroparesis patients. These technological advancements contribute to the expansion and diversification of the Gastroparesis Treatment Market.

Rising rates of regular alcohol and tobacco consumption coupled with an aging population can influence the Gastroparesis Treatment Market by increasing the incidence of gastroparesis, driving demand for effective treatments, presenting challenges in disease management, focusing on prevention and education, and necessitating tailored treatment approaches.

Will Costs and Side Effects of Gastroparesis Treatment Restrain Its Market?

Advanced treatment modalities for gastroparesis, such as gastric electrical stimulation devices or minimally invasive surgical procedures, often come with substantial costs. These costs can make these treatments inaccessible to patients without adequate insurance coverage or financial resources. As a result, a significant portion of the patient population may be unable to afford these advanced therapies, limiting their adoption and impeding market growth.

Increasing incidence of serious side effects associated with gastroparesis drugs may raise concerns about patient safety. Regulatory agencies closely monitor the safety profile of approved medications. They may impose restrictions or warnings based on emerging safety data. Public awareness of safety issues can undermine confidence in certain drugs and dampen market growth by reducing patient and physician acceptance of these treatments.

The regulatory approval process for new gastroparesis drugs can be lengthy and complex. Pharmaceutical companies must conduct extensive preclinical and clinical trials to demonstrate the safety and efficacy of their products, which can take several years and involve significant financial investments. Delays or setbacks in the regulatory approval process can hinder the timely introduction of new treatments to the market, slowing down market growth.

Category-Wise Acumens

How will the Increasing Prevalence of Diabetic Gastroparesis Drive the Growth of the Market?

The diabetic gastroparesis segment is anticipated to hold a major share of the Gastroparesis Treatment Market. Diabetic gastroparesis (DGp) is a neuropathy disorder caused by poorly managed type 1 and type 2 diabetes, ruled out by diagnostic workups, excluding obstruction and potential gastric emptying drugs.

Increasing diabetes mellitus population worldwide enables a high demand for diabetic gastroparesis drugs. According to the IDF data published in September 2021, it is estimated that around 537 million adults will be living with diabetes in 2021. Additionally, the total number of people with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045. It is also estimated that 3 out of 4 adults with diabetes will be living in low- and middle-income countries in 2021. Pharmaceutical companies and researchers are developing drugs for diabetic gastroparesis, driving market growth. Processa Pharmaceuticals initiated a Phase 2A trial for PCS12852, a potential gastroparesis treatment.

Government initiatives aimed at addressing the rising prevalence of diabetes and its complications can indirectly support the Gastroparesis Treatment Market. Policies focused on improving diabetes management, enhancing access to healthcare services, and promoting research and development in gastroenterology can create a conducive environment for market growth.

Incentives such as research grants, regulatory support, and public health campaigns further drive investment in diabetic gastroparesis treatment. Therefore, with the increasing prevalence of diabetes, diabetic gastroparesis is also expected to increase, thus leading to segment growth.

Which Factors Enhance the Use of Prokinetic Agents in Gastroparesis Treatment?

The prokinetic agents segment dominated the market owing to the effectiveness and safety of the drugs that come into this category. Prokinetic agents are a type of medication that increases the contractions of stomach muscles, which helps to improve the overall movement of the stomach. These drugs are often prescribed to patients who are suffering from gastroparesis, a condition that causes symptoms such as nausea and vomiting and hinders digestion.

Prokinetic agents are considered a cornerstone in the treatment of gastroparesis because they address the underlying issue behind the condition. In addition to their role in treating gastroparesis, these drugs have also been studied for their efficiency and safety in critically ill patients receiving enteral nutrition. The results have shown that they are effective in reducing feeding intolerance among such patients.

Also, prokinetic agents can provide effective symptom relief in patients with gastroparesis by reducing the frequency and severity of gastrointestinal symptoms. This includes alleviating nausea, vomiting, abdominal discomfort, and postprandial fullness, which are common manifestations of delayed gastric emptying in gastroparesis patients, thus leading to segment growth.

Country/Region-wise Acumens

Will Advanced Healthcare Infrastructure in North America Mature Gastroparesis Treatment Market?

North America is expected to lead the gastroparesis medicine market due to its aging population and an increase in surgical treatments. The United States is at the forefront of the market, primarily because of its large population with diabetes, favorable reimbursement policies, and increased awareness of the ailment. In June 2022, the CDC reported that 96 million adults in the US have prediabetes, accounting for 38.0% of the adult population. The region's dominance in the industry is due to a rise in healthcare expenditure, a growing hospital population, and well-established infrastructure.

The North American region boasts of an advanced healthcare infrastructure and robust research and development initiatives that foster innovation in treatment options. The well-developed reimbursement systems and insurance coverage in the region also enhance patient access to treatment, leading to an increase in market demand.

Moreover, there is a high prevalence of gastroparesis cases in North America, which is often associated with conditions such as diabetes and post-surgical complications, thereby driving the demand for effective therapies. The growing aging population, which is prone to gastroparesis, coupled with an increasing focus on healthcare technologies, contributes to North America's dominant position in the Gastroparesis Treatment Market. As a result, it continues to lead in terms of market size and influence.

Will Rising Industrialization Enhance Adoption of Gastroparesis Treatment in Asia Pacific?

Rising urbanization and economic expansion in the Asia Pacific region drive the market for gastroparesis treatment by improving healthcare infrastructure, increasing the prevalence of chronic diseases, boosting healthcare spending, and fostering technological advancements and innovation. These factors create a conducive environment for market growth.

Economic growth plays a crucial role in fostering technological advancements and innovation in healthcare. This leads to the development of new diagnostic tools, treatment modalities, and therapeutic approaches for gastroparesis. Healthcare providers in urban areas are fortunate enough to have access to cutting-edge medical technologies and state-of-the-art treatment options. This improved access to healthcare leads to better outcomes for patients and drives market expansion.

Moreover, economic prosperity attracts investments in research and development, leading to the introduction of novel drugs and devices for gastroparesis treatment in the Asia Pacific market.

Competitive Landscape

The competitive landscape of the Gastroparesis Treatment Market is fragmented, with a mix of established players and emerging companies developing novel therapies. Major players focus on medications (prokinetics, antiemetics), while others are involved in medical devices (gastric electric stimulation) and nutritional support methods.

The organizations are focusing on. Rising research and development efforts aim to address the limitations of existing treatments and introduce new options. Some of the prominent players operating in the Gastroparesis Treatment Market include:

• Evoke Pharma, AstraZeneca, Cadila Pharmaceuticals, Neurogastrx, Inc., AbbVie Inc. (Allergan Plc), Marel, Formax, Weber, Devro, Tipper Tie, Handtmann, Middleby Corporation, GEA Group, Evoke Pharma, R. Bard, Inc., Rhythm Pharmaceuticals, Inc., Boston Scientific Corporation, Kimberly-Clark Corporation, Vanda Pharmaceuticals.

Latest Developments

• Disease Type:
• Diabetic gastroparesis
• Idiopathic gastroparesis
• Post-surgical gastroparesis
• Route Of Administration:
• Intravenous
• Nasal
• Oral
• End-Users:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Gastroparesis Treatment Market, By Drug

• Prokinetic Agents
• Antiemetic
• Botulinum Toxin Injections
• Nutritional Support

5. Gastroparesis Treatment Market, By Disease Type

• Diabetic gastroparesis
• Idiopathic gastroparesis
• Post-surgical gastroparesis

6. Gastroparesis Treatment Market, By Route Of Administration

• Intravenous
• Nasal
• Oral

7. Gastroparesis Treatment Market, By End-Users

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

8. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

9. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

10. Competitive Landscape

• Key Players
• Market Share Analysis

11. Company Profiles

• Evoke Pharma
• AstraZeneca
• Cadila Pharmaceuticals
• Neurogastrx, Inc.
• AbbVie Inc. (Allergan Plc)
• Marel
• Formax
• Weber
• Devro
• Tipper Tie
• Handtmann
• Middleby Corporation
• GEA Group
• Evoke Pharma
• R. Bard, Inc.
• Rhythm Pharmaceuticals, Inc.
• Boston Scientific Corporation
• Kimberly-Clark Corporation
• Vanda Pharmaceuticals

12. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

13. Appendix

• List of Abbreviations
• Sources and References